GSK cuts some respiratory targets, keeps others in play

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) cut three respiratory programs against targets largely ignored by the rest of the industry after all three failed to meet efficacy targets in Phase II trials. The pharma disclosed the pruning in its 3Q18 earnings released Wednesday, leaving four other

Read the full 448 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE